According to Blood Cancer United (formerly the Leukemia & Lymphoma Society), approximately every 3 minutes, 1 person in the United States is diagnosed with leukemia, lymphoma, or myeloma. AML is a heterogeneous hematologic malignancy; despite advances in treatment, AML remains challenging to cure. Integrating new treatment options for patients with refractory acute myeloid leukemia (AML), including menin inhibitors, into routine oncology care can help bring novel therapies to patients with relapsed or refractory AML. ACCC is committed to providing information on the latest research and treatment options for blood cancer. In this episode, CANCER BUZZ speaks with Keri Halsema, NP, MSN, RN, nurse practitioner in the Blood Disorders Center at the University of Colorado Anschutz about the factors that influence treatment choices and the use of menin inhibitors to treat relapsed or refractory AML.
"We, as clinicians, are really excited that we have another treatment choice with respect to targeted therapy in these patients that have either the KMT2A rearrangement or the NPM1 mutation…Having outreach and making sure that community oncologists are aware that these medications are available, that various academic centers have various clinical trials that patients may qualify for and may be enrolled in, that's something that's very important in moving care forward for these patients with AML." – Keri Halsema, NP, MSN, RN
Keri Halsema, NP, MSN, RN
Nurse Practitioner
Blood Disorders Center
University of Colorado Anschutz
Aurora, CO
This podcast is made possible by funding and support provided by Kura Oncology.
Resources:
ACCC Educational Video: Best Practices and Solutions for Performing Bone Marrow Biopsies in AML Care
Leukemia & Lymphoma Society Facts and Statistics
